BRCA1 and breast cancer: More recently, effective biomarker-targeted therapies, such as poly (ADP-ribose) polymerase inhibitors (PARPis), have been added to the physicians’ armamentarium for treating BC in the BRCA1/2 germline pathogenic variant (2, 9).